D'AMBROSIO, ROBERTA
D'AMBROSIO, ROBERTA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis
2018 E. Degasperi, A. Aghemo, S. Paolucci, R. D'Ambrosio, M. Borghi, R. Perbellini, F. Novazzi, S. De Nicola, G. Lunghi, F. Baldanti, P. Lampertico
A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients
2012 R. D'Ambrosio, A. Aghemo, M. Rumi, G. Ronchi, M.F. Donato, V. Paradis, M. Colombo, P. Bedossa
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C
2021 S. Varchetta, D. Mele, R. D'Ambrosio, R. Perbellini, A. Lombardi, A. Rojas, S. Paolucci, F. Baldanti, B. Oliviero, S. Mantovani, C. Tinelli, A. De Silvestri, M. Romero Gomez, P. Lampertico, M.U. Mondelli
A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis : the interferon-inducible gene IFI16
2006 M. Mondini, M. Vidali, M. De Andrea, B. Azzimonti, P. Airò, R. D'Ambrosio, P. Riboldi, P. Meroni, E. Albano, Y. Shoenfeld, M. Gariglio, S. Landolfo
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms
2019 R.E. Sharkawy, A. Bayoumi, M. Metwally, A. Mangia, T. Berg, M. Romero-Gomez, M.L. Abate, W.L. Irving, D. Sheridan, G.J. Dore, U. Spengler, P. Lampertico, E. Bugianesi, M. Weltman, L. Mollison, W. Cheng, S. Riordan, R. Santoro, R. Gallego-Durán, J. Fischer, J. Nattermann, R. D’Ambrosio, D. Mcleod, E. Powell, O. Latchoumanin, K. Thabet, M.A.M. Najim, M.W. Douglas, C. Liddle, L. Qiao, J. George, M. Eslam, R. White, A. Rojas, M. Bassendine, C. Rosso, L. Mezzabotta, R. Leung, B. Malik, G. Matthews, J. Grebely, V. Fragomeli, J.R. Jonsson
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study
2014 F. Fabrizi, R. D’Ambrosio, F. Pallotti, L. Berardinelli, P. Messa, P. Martin, A. Aghemo
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review
2014 F. Fabrizi, A. Aghemo, G.B. Fogazzi, G. Moroni, P. Passerini, R. D'Ambrosio, P. Messa
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort
2020 M.G. Quaranta, L. Ferrigno, M. Monti, R. Filomia, E. Biliotti, A. Iannone, G. Migliorino, B. Coco, F. Morisco, M. Vinci, R. D'Ambrosio, L. Chemello, M. Massari, D. Ieluzzi, F.P. Russo, P. Blanc, G. Verucchi, M. Puoti, M.G. Rumi, F. Barbaro, T.A. Santantonio, A. Federico, L. Chessa, I. Gentile, M. Zuin, G. Parruti, G. Morsica, L.A. Kondili
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C
2015 R. D'Ambrosio, A. Aghemo, M. Colombo
Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series
2022 S. Pelusi, L. Ronzoni, F. Malvestiti, C. Bianco, I. Marini, R. D'Ambrosio, J.A. Giannotta, G. Soardo, M. Maggioni, D. Prati, L. Valenti
Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19
2020 M.A. Iavarone, R. D'Ambrosio, P. Lampertico
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review)
2014 F. Fabrizi, A. Aghemo, G. Moroni, P. Passerini, R. D'Ambrosio, P. Martin, P. Messa
Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy
2021 G. Tosetti, E. Degasperi, E. Farina, R. D'Ambrosio, R. Soffredini, M. Borghi, V. La Mura, M. Primignani, P. Lampertico
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study
2022 L. Valenti, S. Pelusi, A. Aghemo, S. Gritti, L. Pasulo, C. Bianco, C. Iegri, G. Cologni, E. Degasperi, R. D'Ambrosio, P. del Poggio, A. Soria, M. Puoti, I. Carderi, M.G. Pigozzi, C. Carriero, A. Spinetti, V. Zuccaro, M. Memoli, A. Giorgini, M. Vigano, M.G. Rumi, T. Re, O. Spinelli, M.C. Colombo, T. Quirino, B. Menzaghi, G. Lorini, A. Pan, A. D'Arminio Monforte, E. Buscarini, A. Autolitano, P. Bonfanti, N. Terreni, G. Aimo, M. Mendeni, D. Prati, P. Lampertico, M. Colombo, S. Fagiuoli
Editorial : good news to patients with thalassaemia HCV clearance made easy with direct-acting antivirals
2017 R. D'Ambrosio, P. Lampertico
Editorial: the role for PIVKA-II measurement after HCV elimination by direct-acting antivirals in terms of prediction of hepatocellular carcinoma—authors' reply
2022 E. Degasperi, R. D'Ambrosio, P. Lampertico
Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients
2019 R. D'Ambrosio, M. Vinci, M. Franchina, L. Parlati, S. Zaltron, L. Pasulo, M. Campise, P. Messa, S. Pol, P. Lampertico
Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis
2017 A. Tripodi, R. D'Ambrosio, L. Padovan, G. Tosetti, A. Aghemo, M. Primignani, V. Chantarangkul, F. Peyvandi, M. Colombo
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease
2019 G. Tosetti, M. Primignani, V. La Mura, R. D'Ambrosio, E. Degasperi, N. Mezzina, M. Viganò, M. Rumi, A.L. Fracanzani, R. Lombardi, S. Fargion, M. Fraquelli, A. Aghemo, P. Lampertico
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin
2016 E. Degasperi, S. DE NICOLA, M. Rumi, R. D'Ambrosio